Comparative Pharmacology
Head-to-head clinical analysis: GEFITINIB versus RETEVMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GEFITINIB versus RETEVMO.
GEFITINIB vs RETEVMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor; inhibits EGFR autophosphorylation and downstream signaling, leading to cell cycle arrest and apoptosis in EGFR-overexpressing tumors.
RETEVMO (selpercatinib) is a potent and selective RET kinase inhibitor. It inhibits wild-type RET and multiple RET fusions (e.g., KIF5B-RET, CCDC6-RET) and mutations (e.g., M918T, C634W, V804M/L/E) by binding to the ATP-binding site of RET, blocking downstream signaling pathways including MAPK/ERK and PI3K/AKT, thereby inhibiting tumor cell proliferation.
250 mg orally once daily
160 mg orally twice daily
None Documented
None Documented
Terminal half-life 48 hours (range 24-85 hr); supports once-daily dosing, steady state achieved by day 7-10
Clinical Note
moderateGefitinib + Digoxin
"Gefitinib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateGefitinib + Digitoxin
"Gefitinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateGefitinib + Deslanoside
"Gefitinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateGefitinib + Acetyldigitoxin
"Gefitinib may decrease the cardiotoxic activities of Acetyldigitoxin."
18 hours (terminal elimination half-life) supporting twice-daily dosing; steady-state reached within ~3 days.
Primarily fecal (86% unchanged + metabolites), renal excretion <5%
Primarily biliary/fecal (approximately 75% of administered dose recovered in feces as unchanged drug and metabolites); renal elimination accounts for <10% (mostly metabolites).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor